Total synthesis of the ionophore antibiotic X-14547A (Indanomycin)

Martin P. Edwards(Pfizer (United States)), David J. Williams(Royal Devon & Exeter NHS Foundation Trust), Steven V. Ley(University of Cambridge), Simon Lister, Brian D. Palmer

The Journal of Organic Chemistry

September 1, 1984

10.1021/jo00193a014

Cited by 83

Related Papers

Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)

|Journal of Medicinal Chemistry|2011|924

Targeting C-reactive protein for the treatment of cardiovascular disease

|Nature|2006|676

Discovery of (10 <i>R</i> )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- <i>2H</i> -8,4-(metheno)pyrazolo[4,3- <i>h</i> ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations

|Journal of Medicinal Chemistry|2014|587

Using the Golden Triangle to optimize clearance and oral absorption

|Bioorganic & Medicinal Chemistry Letters|2009|382

Lipophilic Efficiency as an Important Metric in Drug Design

|Journal of Medicinal Chemistry|2018|340